Medco Completes Acquisition of United BioSource Corporation
Medco Health Solutions
on Thursday completed its acquisition of
United BioSource Corporation
in an all-cash transaction valued at approximately $730 million, creating a complementary and comprehensive research organization that extends Medco's core capabilities in data analytics and research to accelerate pharmaceutical knowledge.
UBC is now a wholly-owned subsidiary of Medco that will run independently from Medco's core business to ensure compliance with contractual requirements and client expectations. Dr. Robert S. Epstein, Medco's chief medical officer and president of the Medco Research Institute™, will have overall responsibility for the UBC business. UBC Chief Executive Officer Ethan Leder will continue in his position, overseeing the company's current operations.
The transaction was funded with the proceeds of Medco's recently completed senior notes offering. The new business is expected to be slightly accretive to Medco shareholders in 2011, excluding one-time items and amortization.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
